It seems we can’t find what you’re looking for. Perhaps searching can help.
David Sinclair, a distinguished professor in the Department of Genetics and co-director of the renowned Paul F. Glenn Center for the Biology of Aging at Harvard Medical School, leads groundbreaking research on sirtuins. These protein-modifying enzymes respond to fluctuations in NAD+ levels and caloric restriction, playing a vital role in various areas of study including chromatin, energy metabolism, mitochondria, learning and memory, neurodegeneration, cancer, and cellular reprogramming.
With an innovative perspective, Sinclair posits that aging should be regarded as a disease, and he envisions a future where we possess the means to put it into remission. He fervently emphasizes the imperative for global attention to the social, economic, and political ramifications of a world where billions can enjoy extended and healthier lifespans.
Furthermore, Sinclair’s contributions extend beyond academia, as he co-founded several biotechnology companies such as Life Biosciences, Sirtris, Genocea, Cohbar, MetroBiotech, ArcBio, and Liberty Biosecurity, and actively serves on the boards of various others.
Notably, he is also the esteemed co-founder and co-chief editor of the esteemed journal Aging, showcasing his commitment to advancing scientific knowledge in the field. Sinclair’s exceptional expertise is evidenced by his impressive portfolio, boasting 35 patents as an inventor and being the recipient of over 35 esteemed awards and honors. Time Magazine recognized his profound impact by including him on their prestigious “100 Most Influential People in the World” list in 2014, while also acknowledging him as one of the top 50 individuals in healthcare in 2018.